Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Expert Opin Biol Ther
; 22(2): 313-320, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-34904510
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
Colitis, Ulcerative
/
Biosimilar Pharmaceuticals
Type of study:
Observational_studies
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Expert Opin Biol Ther
Journal subject:
BIOLOGIA
/
TERAPEUTICA
Year:
2022
Document type:
Article
Affiliation country:
Italia
Country of publication:
Reino Unido